Significant Setbacks: Why Celgene’s No Longer the Biotech Outperformer It Once Was
December 27, 2017 at 12:01 PM EST
A downgrade based on Celgene's drug setbacks is weighing on the biotech's stock today.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.